Quantitative measurement of Schizophrenia using Electrovestibulography.

据估计，2001年精神分裂症的花费约为18.5亿澳元（占GDP的0.3%，37，000名澳大利亚人每人花费近5万澳元）。超过三分之一的费用由患者及其护理人员承担。误诊和不正确的治疗是常见的。迄今为止，对精神分裂症的定量评估是不可能的，这使得这一工具可能是无价的。一个准确的诊断测试可以促进早期诊断，更准确的治疗计划，并预防患者的衰弱精神病发作。通过能够监测药物疗效，社区可以受益于降低药物成本、缩短住院时间和加快新药开发。

Schizophrenia was estimated to cost approximately $1.85billion in 2001 (0.3% of GDP and nearly $50k for each of the 37,000 Australians with the illness). Over one third of the cost is borne by sufferers and their carers. Misdiagnosis and incorrect therapy are common. To date quantitative assessment of Schizophrenics has been impossible making this tool potentially invaluable. An accurate diagnostic test could facilitate earlier diagnosis, more accurate treatment plans, and prevention of debilitating psychotic episodes for the sufferer. By being able to monitor drug efficacy the community can benefit by reduced drug costs, confinement times and hastened new drug development.